CClinicalTrials.gg
CompletedNCT04169477CROSS-TENSUpdated Jan 11, 2023

Comparison of Two Modes of Transcutaneous Electrical Nerve Stimulation (TENS) in Chronic Neuropathic Radiculalgia

An interventional study of CEFAR Primo Pro (TENS device) in Neuropathic Pain and Radiculopathy, sponsored by Lille Catholic University. Completed at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-11.

Sponsored by Lille Catholic University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will compare 2 types of Transcutaneous Electrical Nerve Stimulation (TENS) to treat chronic neuropathic pain. TENS involves the application of electrical stimulation to the skin via surface electrodes to stimulate nerve fibres for pain relief.

Read the detailed description

TENS is already recommended in clinical practice to treat chronic neuropathic pain. The objective of this study is to compare the efficacy of 2 different modes of TENS: conventional TENS (c-TENS) and mixed-frequency TENS (m-TENS). Randomization will determine the mode that the patient has to test during the first month.

Each patient will test successively each mode during 1 month at home (3 sessions 1 hour/day). Then, the patient will test the other mode during the second month. Up to 6 months, the patient will be free to use the mode of TENS he wants.

02

Conditions studied

  • Neuropathic Pain
  • Radiculopathy

Keywords

  • TENS
03

In context

Neuralgia

1,287 studies on the registry are indexed under Neuralgia; 256 are open to participants now.

This study's enrollment of 74 is above the median of 52 across 973 interventional studies indexed under Neuralgia.

Browse Neuralgia studies →

Lead sponsor

Lille Catholic University is the lead sponsor of 111 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients aged 18 years old or older
  • Patients with chronic neuropathic radiculalgia from at least 3 months of evolution
  • Radiculalgia VAS > or egal to 40/100
  • Neuropathic pain diagnostic (DN4) score > or egal to 4
  • Patient who has accepted to participate in the study by signing the informed consent form

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Dermatosis in the painful dermatome
  • Venous or arterial thrombosis of the lower limbs
  • Patient with active implantable medical device
  • Severe cognitive disorders
  • Patient under a legal protection regime(guardianship/curatorship/guardianship of justice)
  • Previous use of TENS to treat radiculalgia
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
74 participants (actual)

Study arms

  • Experimental
    cTENS-mTENS

    Patients randomized in this arm will test cTENS mode first, the subjects will be crossed over to the mTENS form

    Device: CEFAR Primo Pro (TENS device)

  • Experimental
    mTENS-cTENS

    Patients randomized in this arm will test mTENS mode first, the subjects will be cross over to the cTENS mode

    Device: CEFAR Primo Pro (TENS device)

Interventions

  • DeviceCEFAR Primo Pro (TENS device)

    During the first month: Patients will have to test 3 sessions of TENS 1 hour/day. Depending on their arm assigned by randomization, patients will begin with c-TENS or m-TENS. \[Cross-over\] During the second month: Patients will test the other type they do not have used yet according to the following scheme: 3 sessions of 1 hour, each day. In this way, all patients will test successively the 2 different modes. After the end of the second month and up to the end of their participation (6 months after randomization) patients will be free to use the mode of TENS they prefer.

06

What researchers measure

Primary outcomes

  1. Change in the visual analog scale for evaluation of radiculalgia (from 0 to 100)

    Visual analogue scales are 10-cm lines anchored at the ends by words that define the bounds of various pain dimensions. The patient is asked to place a vertical mark on the scale to indicate the level of intensity of his or her pain being 0 equivalent to no pain and 100 to the worst possible pain

    Time frame: day 30, day 60

Secondary outcomes

  1. Patient preference rate

    After having tested each mode during one month, the patients will be asked to give their preference (c-TENS or m-TENS)

    Time frame: day 60

  2. Patient Global Impression of Change (PGIC)

    Patient Global Impression of Change is a 7-point scale used by the patient to rate the severity of the patient's illness at the time of assessment being 1 equivalent to no change or worsening and 7 to very much improved, making a difference

    Time frame: day 30, day 60

  3. Rate of patient compliance

    Rate of TENS sessions completed by the patient compared to the number of sessions prescribed for each mode

    Time frame: day 30, day 60

  4. Rate of patients with adverse events

    Rate of patients with adverse events definitely or possibly attributable to neurostimulation for each type

    Time frame: day 30, day 60, day 180

  5. Brief pain inventory (impact on daily life) (BPI)

    The BPI allows patients to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function. There are line drawings of the front and back of a human body on which patients mark the location of their pain. In addition, patients fill out 11 different questions about pain intensity (present as well as least, most, and average for the past 24 hours) and the effect of the pain on their ability to function during various activities of daily living (pain interference items) rated on 0-10 scales being equivalent to no interference and 10 to complete interference.

    Time frame: day 30, day 60

  6. Mean of post-effect delay

    for each mode of TENS, patient estimation between end of a TENS session and return to initial intensity of the pain (calculated from patient journal completed every day during the 2 first months of the study

    Time frame: day 60

  7. Visual analog scale for evaluation of radiculalgia one month after

    Visual analogue scales are 10-cm lines anchored at the ends by words that define the bounds of various pain dimensions. The patient is asked to place a vertical mark on the scale to indicate the level of intensity of his or her pain being 0 equivalent to no pain and 100 to the worst possible pain

    Time frame: day 30, day 60

  8. Visual analog scale for evaluation of radiculalgia six months after

    Visual analogue scales are 10-cm lines anchored at the ends by words that define the bounds of various pain dimensions. The patient is asked to place a vertical mark on the scale to indicate the level of intensity of his or her pain being 0 equivalent to no pain and 100 to the worst possible pain

    Time frame: day 180

  9. Rate of therapeutic persistence according toTENS mode

    Time frame: day 180

07

Study locations

4 sites
  • CH Béthune
    Béthune, 62408, France
  • CHU Lille
    Lille, 59037, France
  • GHICL
    Lomme, 59462, France
  • CH Roubaix
    Roubaix, 59100, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04169477
Lead sponsor
Lille Catholic University
Responsible party
Sponsor
First posted
Nov 20, 2019
Start date
Oct 8, 2019
Primary completion
May 5, 2022
Completion
Oct 5, 2022
Last update
Jan 11, 2023

Study contacts

Vincent Ducoulombier, MD
principal investigator · GHICL

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion